Cardiac Biomarkers Market Size and Share
Cardiac Biomarkers Market Analysis by Mordor Intelligence
The cardiac biomarkers market size stood at USD 18.91 billion in 2025 and is forecast to reach USD 35.56 billion by 2030, advancing at a 13.46% CAGR. Adoption of high-sensitivity assays, rapid point-of-care platforms and AI-driven decision support systems is accelerating test volumes as health systems pursue earlier rule-out strategies for acute coronary events. Expansion of public- and private-sector proteomics funding is widening the discovery pipeline, while the FDA’s first point-of-care high-sensitivity cardiac troponin approval in 2024 has shortened emergency department rule-out times from one hour to 17 minutes. Demand is further reinforced by the 127.9 million American adults living with cardiovascular disease, equivalent to 48.6% of the population. Meanwhile, Asia-Pacific regulatory modernization is creating attractive reimbursement-linked growth prospects for novel biomarkers and decentralized testing platforms.
Key Report Takeaways
- By biomarker type, troponins held 59.87% of the cardiac biomarkers market share in 2024, while ischemia-modified albumin is projected to expand at a 14.21% CAGR to 2030.
- By application, myocardial infarction led with 40.23% revenue share in 2024; acute coronary syndrome is forecast to grow at a 14.27% CAGR through 2030.
- By location of testing, central laboratories accounted for 58.98% share of the cardiac biomarkers market size in 2024, while point-of-care platforms are advancing at a 14.38% CAGR to 2030.
- By end user, hospitals commanded 53.88% share in 2024; home healthcare settings record the fastest CAGR at 14.58% through 2030.
- By region, North America captured 42.21% of the cardiac biomarkers market share in 2024, yet Asia-Pacific will register the highest CAGR at 14.52% to 2030.
Global Cardiac Biomarkers Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Increasing prevalence of cardiovascular diseases | +3.2% | Global, highest in North America & Europe | Long term (≥ 4 years) |
Technological advances in high-sensitivity assays | +2.8% | Global, led by North America & Europe | Medium term (2-4 years) |
Growing public- & private-sector R&D funding | +2.1% | Global, concentrated in developed markets | Long term (≥ 4 years) |
Expansion of multiplex panels for early rule-out protocols | +1.9% | North America & Europe, expanding to Asia-Pacific | Medium term (2-4 years) |
AI-enabled predictive analytics integrating troponins with EHRs | +1.7% | North America & Europe, select Asia-Pacific | Medium term (2-4 years) |
Adoption of at-home finger-stick cardiac biomarker kits | +1.4% | Global, early adoption in developed markets | Short term (≤ 2 years) |
Source: Mordor Intelligence
Increasing prevalence of cardiovascular diseases
Cardiovascular disorders remain the top global mortality driver, costing the United States USD 422.3 billion annually in direct medical expenses [1]Seth S. Martin, "2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association," American Heart Association, heart.org. Mandated ASCVD risk assessment coding under the CMS 2025 Physician Fee Schedule now requires evidence-based diagnostics that combine demographic variables with laboratory cardiac biomarkers, intensifying institutional uptake [2]Centers for Medicare & Medicaid Services, "Calendar Year (CY) 2025 Medicare Physician Fee Schedule Final Rule," cms.gov. As value-based care contracts expand, providers rely on biomarker-guided interventions to document measurable outcome gains and avoid readmission penalties.
Technological advances in high-sensitivity assays
FDA clearance of Siemens Healthineers’ Atellica IM high-sensitivity troponin I test enables prognostic risk stratification for up to one year after an index event [3]Siemens Healthineers AG, "For Patients at Risk, a Simple Blood Test Can Help Doctors Predict Likelihood of Future Heart Attack, Other Cardiac Events, and Death," siemens-healthineers.com. Laboratory-quality microfluidic cartridges now quantify troponin at 10-fold lower concentrations than legacy assays and deliver results in minutes, achieving 100% sensitivity in multi-center validation studies. Sex-specific reference ranges are closing historical diagnostic gaps among female patients, while integrated biosensors allow finger-stick whole-blood testing without plasma separation.
Growing public- & private-sector R&D funding
Thermo Fisher Scientific’s USD 3.1 billion acquisition of Olink boosts high-throughput proteomics capacity to interrogate 5,400 proteins across 600,000 UK Biobank samples—the world’s largest human proteome initiative. NIH grants are financing low-cost electrochemical sensors capable of saliva-based detection for USD 3.00 per unit, supporting rural screening programs. Private equity interest remains strong in start-ups delivering multiplex point-of-care analyzers that shorten emergency department throughput times.
Expansion of multiplex panels for early rule-out protocols
Implementation of 0/2-hour high-sensitivity troponin pathways has attained 91.1% sensitivity and 98.1% negative predictive value for 30-day cardiac events. Combining troponin with cardiac myosin-binding protein C in a single cartridge yields an AUC of 0.917, bridging diagnostic blind spots for transient ischemia. Use of HEART-CT algorithms reclassified 76.7% of moderate-risk patients to safe discharge, cutting average emergency department stay to 4.6 hours.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Stringent regulatory frameworks | -2.1% | Global, most stringent in North America & Europe | Long term (≥ 4 years) |
Reimbursement erosion from bundled-payment models | -1.8% | North America, expanding to Europe | Medium term (2-4 years) |
Analytical variability of novel POC devices | -1.3% | Global, particularly in emerging markets | Short term (≤ 2 years) |
Limited specificity generating false-positive results | -1.1% | Global, higher impact in low-resource settings | Medium term (2-4 years) |
Source: Mordor Intelligence
Stringent regulatory frameworks
Europe’s In-Vitro Diagnostic Regulation now obliges extensive clinical evidence, stretching CE-mark timelines. SpinChip Diagnostics expects to submit under IVDR by end-2025 with launch slated for 2026, illustrating prolonged pathways. In the United States, FDA draft rules for AI-enabled diagnostics require algorithmic transparency plus multi-ethnic validation cohorts, adding compliance costs and delaying commercial roll-out.
Reimbursement erosion from bundled-payment models
The CMS 2025 fee schedule reduces conversion factors by 2.83% while broadening ASCVD risk-assessment coverage, forcing providers to justify biomarker utilization on cost-per-episode grounds. Accountable Care Organizations risk margin compression if testing protocols do not translate into reductions in readmissions or length of stay. Private insurers mirror these bundled structures, prompting laboratories to negotiate value-based contracts.
Segment Analysis
By Biomarker Type: Troponins anchor adoption, novel markers accelerate
Troponins controlled 59.87% of the cardiac biomarkers market in 2024, validating decades of clinical trust in these gold-standard proteins. Segment revenues benefit from the shift to high-sensitivity formats that detect minute myocardial injury within two hours of symptom onset. Conversely, ischemia-modified albumin is expanding at a 14.21% CAGR, reflecting growing recognition that transient coronary vasospasm events demand markers able to capture reversible ischemia that troponin misses.
The cardiac biomarkers market size attributable to troponins reached USD 11.3 billion in 2025. Manufacturers are augmenting assay menus with microRNAs and inflammatory proteins, yet clinical uptake hinges on regulatory clearance and guideline endorsement. Creatine kinase is tapering as high-sensitivity troponins deliver superior specificity, while myoglobin remains a legacy option used primarily for ultra-early triage before troponin rises.
Note: Segment shares of all individual segments available upon report purchase
By Application: Acute coronary syndrome protocols shape growth
Applications in myocardial infarction generated 40.23% of segment revenue for the cardiac biomarkers market in 2024. Hospitals rely on troponin algorithms to meet door-to-needle targets, a metric directly tied to reimbursement bonuses. Acute coronary syndrome, however, is climbing at a 14.27% CAGR, driven by 0/2-hour rule-out pathways that safely discharge low-risk patients and decrease telemetry bed occupancy.
The cardiac biomarkers market size for acute coronary syndrome is estimated to be underpinned by payer incentives that reward avoidance of unnecessary admissions. Chronic care settings are also expanding use cases; BNP-based management of heart failure reduces readmission penalties under the Medicare Hospital Readmissions Reduction Program, while ASCVD coding requirements integrate biomarker panels into annual risk reviews.
By Location of Testing: Point-of-care transformation intensifies
Central laboratories preserved a 58.98% revenue share in 2024, leveraging high-throughput analyzers and consolidated procurement contracts. Yet point-of-care systems are advancing at a 14.38% CAGR thanks to FDA-cleared platforms delivering high-sensitivity troponin I results in 17 minutes. Emergency physicians value near-patient testing that avoids transport lag, improving adherence to 60-minute turnaround benchmarks.
Point-of-care expansion is further accelerated by acquisition activity; bioMérieux’s EUR 138 million SpinChip purchase adds a 10-minute whole-blood immunoassay cartridge that rivals central-lab precision. Cost of ownership is narrowing as microfluidic manufacturing scales, enabling community hospitals and ambulatory surgery centers to deploy decentralized analyzers without extensive infrastructure.

Note: Segment shares of all individual segments available upon report purchase
By End User: Home healthcare emerges as a catalyst
Hospitals commanded 53.88% of demand in 2024, yet home healthcare settings are projected to deliver a 14.58% CAGR through 2030. Portable saliva-based sensors now quantify galectin-3 and S100A7 within 15 minutes at USD 3.00 unit cost, supporting at-home monitoring for chronic cardiac patients. Integration of Bluetooth-enabled cartridges into telehealth apps allows clinicians to trend serial values remotely.
The cardiac biomarkers market size allocated to home use could surpass USD 5 billion by 2030, propelled by payer support for remote physiologic monitoring codes and patient preference for in-home sampling. Diagnostic laboratories retain relevance for complex multiplex panels, while ambulatory clinics leverage handheld analyzers for perioperative risk stratification.
Geography Analysis
North America captured 42.21% of the cardiac biomarkers market in 2024, supported by well-funded payers, mature laboratory networks and guideline alignment that validates high-sensitivity assays. CMS coding updates further entrench biomarker requirements within preventative cardiology workflows. The region’s testing volumes will keep pace with population aging, yet pricing pressure from bundled payment models is likely to temper revenue expansion.
Europe follows as the second-largest region, with public healthcare systems anchoring troponin adoption for rapid rule-out protocols. Implementation of the In-Vitro Diagnostic Regulation increases compliance costs but also elevates trust in clinically validated assays, reinforcing adoption across Germany, France and the United Kingdom. Market momentum will hinge on balancing reimbursement ceilings with cost-effective multiplex panels that reduce downstream imaging utilization.
Asia-Pacific is the fastest-growing territory, poised to post a 14.52% CAGR. Japan’s USD 40 billion medical device sector is already embracing high-sensitivity troponin and BNP testing, aided by PMDA expedited review channels. China’s National Medical Products Administration has approved 61 innovative diagnostics in 2023, signaling a friendlier path for foreign and domestic biomarker vendors. Rising cardiovascular prevalence, coupled with government insurance expansion, drives demand for decentralized point-of-care solutions in secondary hospitals.
Middle East & Africa and South America represent emerging catch-up markets. Gulf Cooperation Council states are investing in tertiary cardiac centers equipped with high-throughput analyzers, while Brazil and Mexico roll out universal health coverage pilots that reimburse early myocardial infarction diagnostics. Suppliers able to deliver affordable, stable ambient-temperature reagents will gain share as freight and cold-chain constraints persist.

Competitive Landscape
The cardiac biomarkers market remains moderately fragmented, with leading companies carving out niches through acquisitions, assay innovation and digital integration. bioMérieux’s SpinChip purchase consolidates near-patient testing assets and accelerates time-to-result to 10 minutes for whole-blood immunoassays, directly challenging Abbott’s i-STAT and Roche’s cobas h 232 portfolios. Siemens Healthineers differentiates via prognostic claims on its high-sensitivity troponin I, extending utility beyond diagnosis into one-year risk stratification.
Thermo Fisher Scientific’s Olink acquisition positions it at the discovery frontier, leveraging proximity extension assays to uncover novel proteins with potential cardiac relevance. Beckman Coulter and Ortho Clinical Diagnostics focus on menu breadth inside core labs, bundling cardiac markers with infectious disease panels for automated analyzers to protect reagent annuities. Start-ups such as RCE Technologies pursue continuous, wearable transdermal monitoring that could redefine chronic care paradigms once regulatory hurdles are cleared.
Competitive differentiation increasingly rests on embedded analytics. Vendors are integrating cloud dashboards that plot serial troponin curves against machine-learning risk scores, delivering actionable flags to physicians within electronic health records. Interoperability and cybersecurity are becoming procurement gate-checks as health systems align with zero-trust frameworks. Companies offering subscription-based decision-support modules may capture annuity revenue even as reagent prices face downward pressure.
Cardiac Biomarkers Industry Leaders
-
Abbott Laboratories
-
Becton, Dickinson and Company
-
BioMérieux
-
Bio-Rad Laboratories, Inc.
-
Danaher Corporation
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- January 2025: bioMérieux completed acquisition of SpinChip Diagnostics for EUR 138 million, adding a 10-minute whole-blood immunoassay platform slated for launch in 2026.
- June 2024: Siemens Healthineers added the NT-proBNP II assay to its Atellica Solution, enabling labs to choose between BNP and NT-proBNP for heart-failure evaluation.
- April 2024: RCE Technologies reported first-in-human pilot results for its Infrasensor wearable that continuously tracks transdermal cardiac biomarkers.
- March 2024: Diasorin’s LIAISON PLEX platform received FDA clearance, broadening U.S. access to advanced cardiac biomarker panels.
Global Cardiac Biomarkers Market Report Scope
As per the scope of the report, cardiac biomarkers are of great importance in the timely and accurate diagnosis and management of acute coronary syndrome, as well as the prognosis. The Cardiac Biomarkers Market is segmented by Type (Creatine Kinase, Troponins, Myoglobin, Ischemia Modified Albumin, and Other Types), Application (Congestive Heart Failure, Acute Coronary Syndrome, Myocardial Infarction, Atherosclerosis, and Other Applications), Location of Testing (Point-of-Care Testing and Laboratory Testing), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers market sizes and forecasts in terms of value (USD million) for all the above segments.
By Biomarker Type | Troponins | ||
Creatine Kinase | |||
Myoglobin | |||
Ischemia-Modified Albumin | |||
Other Biomarker Type | |||
By Application | Acute Coronary Syndrome | ||
Myocardial Infarction | |||
Congestive Heart Failure | |||
Atherosclerosis | |||
Other Applications | |||
By Location of Testing | Point-of-care Testing | ||
Central Laboratory Testing | |||
By End-user | Hospitals | ||
Diagnostic Laboratories | |||
Ambulatory Surgery Centers & Clinics | |||
Home Healthcare Settings | |||
Others | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Troponins |
Creatine Kinase |
Myoglobin |
Ischemia-Modified Albumin |
Other Biomarker Type |
Acute Coronary Syndrome |
Myocardial Infarction |
Congestive Heart Failure |
Atherosclerosis |
Other Applications |
Point-of-care Testing |
Central Laboratory Testing |
Hospitals |
Diagnostic Laboratories |
Ambulatory Surgery Centers & Clinics |
Home Healthcare Settings |
Others |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the current size of the cardiac biomarkers market?
The cardiac biomarkers market size stands at USD 18.91 billion in 2025 and is projected to reach USD 35.56 billion by 2030.
Which biomarker segment dominates the cardiac biomarkers market?
Troponins dominate, accounting for 59.87% share of 2024 revenues, thanks to guideline endorsement for myocardial infarction diagnosis.
How fast is the point-of-care segment growing?
Point-of-care cardiac biomarker testing is expanding at a 14.38% CAGR through 2030, driven by 17-minute high-sensitivity troponin assays.
Why is Asia-Pacific the fastest-growing region?
Regulatory modernization in Japan and China, combined with rising cardiovascular incidence, is propelling a 14.52% regional CAGR.
What impact will bundled payments have on test utilization?
Bundled payment models reduce per-test reimbursement, compelling providers to prove that biomarker-guided pathways cut readmissions and total episode costs.
Which recent acquisition reshaped the competitive landscape?
BioMérieux’s EUR 138 million takeover of SpinChip Diagnostics in 2025 strengthened its near-patient testing portfolio with a 10-minute immunoassay platform.
Page last updated on: June 25, 2025